Y-Intercept (HK)’s CRISPR Therapeutics CRSP Stock Holding History

Y-Intercept (HK)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$814K	Buy	+14,711	New	+$794K	0.02%	1099
2025 Q3	–	Sell	-39,161	Closed	-$1.9M	–	1645
2025 Q2	$1.9M	Buy	+39,161	New	+$1.52M	0.05%	627
2021 Q3	–	Sell	-3,716	Closed	-$602K	–	692
2021 Q2	$602K	Sell	3,716 -3,732	-50%	-$454K	0.15%	216
2021 Q1	$858K	Buy	+7,448	New	+$1.12M	0.23%	128

Other funds holding CRSP

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Y-Intercept (HK)'s CRSP Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 14,711 shares worth $814K. The stake represents 0.02% of the portfolio and ranks #1099 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in CRSP as recently as Q2 2025.

Y-Intercept (HK) first reported a position in CRSP in Q1 2021 and has held it in 4 quarters since. The position peaked at $1.9M in Q2 2025. 286 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

Y-Intercept (HK) held 14,711 shares of CRISPR Therapeutics worth $814K as of Q3 2026.
CRISPR Therapeutics was a new Y-Intercept (HK) position in Q3 2026.
CRISPR Therapeutics made up 0.02% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1099 holding.
Y-Intercept (HK) first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 4 quarters since.
Y-Intercept (HK)'s CRISPR Therapeutics position peaked at $1.9M in Q2 2025.
286 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.